Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.

Publication date: Dec 03, 2024

SARS-CoV-2 asymptomatic surveillance testing (AST) is a common strategy to minimize the risk of nosocomial infection in patients and healthcare personnel. In contrast to admission screening, post-admission AST was less widely adopted. This study describes the diagnostic yield of post-admission serial SARS-COV-2 testing in hospitalized patients at a large cancer center with mostly double-occupancy rooms. Retrospective cohort study design. Post-admission SARS-CoV-2 tests were examined over a 18 month study period. Positive results were reviewed to determine true hospital-onset infections using a combination criteria of screening all sample cycle threshold (Ct) values >30, results of non-concordant repeat testing, and clinical symptoms. Post-admission serial testing of 15,048 hospitalized patients during an 18-month study period at a tertiary care cancer center detected hospital-onset infection in 1. 6% (n = 245 patients). Among all hospital-onset positive SARS-CoV-2 RNA tests, 13% were clinically false positive. Most true infections were mild to moderate in severity. In summary, post-admission serial testing in a high-risk setting is a low-yield strategy with several unfavorable effects and should no longer be routinely applied.

Concepts Keywords
Asymptomatic Admission
Cancer Ast
Ct Cov
Healthcare Hospital
Routinely Hospitalized
Infection
Onset
Positive
Post
Risk
Sars
Screening
Serial
Testing
Yield

Semantics

Type Source Name
disease MESH cancer
disease MESH nosocomial infection
disease MESH infections
disease IDO infection

Original Article

(Visited 2 times, 1 visits today)